Smith & Nephew SNATS, Inc. (NYSE:SNN) Given Average Rating of “Hold” by Brokerages

Smith & Nephew SNATS, Inc. (NYSE:SNN) has been given an average rating of “Hold” by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $30.9250.

Several research firms have recently weighed in on SNN. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday, May 11th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, Weiss Ratings downgraded Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th.

Institutional Investors Weigh In On Smith & Nephew SNATS

Several large investors have recently modified their holdings of the company. Garner Asset Management Corp acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth $27,000. Arax Advisory Partners lifted its holdings in shares of Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 569 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Smith & Nephew SNATS during the third quarter worth $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth $43,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Price Performance

Shares of SNN opened at $30.11 on Friday. Smith & Nephew SNATS has a 52-week low of $28.78 and a 52-week high of $38.79. The stock has a 50 day moving average price of $31.15 and a 200 day moving average price of $32.75. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN) last posted its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The firm had revenue of $1.60 billion during the quarter. Equities analysts predict that Smith & Nephew SNATS will post 2.22 earnings per share for the current fiscal year.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.